Glazer Capital LLC’s Revance Therapeutics, Inc. RVNC Stock Holding History

Glazer Capital LLC’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,950,000	Closed	-$5.93M	–	218
2024 Q4	$5.93M	Buy	+1,950,000	New	+$8.49M	0.4%	40

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Glazer Capital LLC's RVNC Position: Q1 2025 in Review

Glazer Capital LLC sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,950,000 shares — an estimated $5.93M sold.

Glazer Capital LLC first reported a position in RVNC in Q4 2024 and held it in 1 quarter. The position peaked at $5.93M in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Glazer Capital LLC reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Glazer Capital LLC sold 1,950,000 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $5.93M.
Glazer Capital LLC first reported a position in Revance Therapeutics, Inc. in Q4 2024 and held it in 1 quarter.
Glazer Capital LLC's Revance Therapeutics, Inc. position peaked at $5.93M in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Glazer Capital LLC's 13F filing for Q1 2025, filed 15 May 2025.